Cancer related research continues to grow. One fairly successful in increasing life expectancy of patients with advanced cancer is a targeted therapy at the cellular level. However, not all cancer patients fit with the therapy.
In contrast to conventional cancer treatments such as chemotherapy or radiotherapy that attacks all cells, both cancer cells and healthy cells, targeted therapy only attack the cancer cells or cells that undergoing uncontrolled division.
Cancer targeted therapy affects only certain molecules that play a role in the growth of cancer cells so that the growth and spread can be inhibited. This therapy is considered more effective.
Some types of cancer that can be treated in this way include lung cancer, certain types of breast cancer, skin cancer, certain types of blood cancer, and colorectal cancer. Cancer treatment with targeted therapies aimed at patients with advanced cancer. The cost is also quite expensive.
According to Ahmad R Utomo, Ph.D., Researcher from Kalbe Genomics Laboratory, drugs in the treatment of the target will give good results if matched genetic mutation. Therefore before being given treatment required examination of genetic profiles.
“Doctors today do not just look at the organ affected by cancer, but also their genetic profile. The goal is to select the patient so that the provision of appropriate medication,” he said in the event of media education held by PT. Kalbe Farma.
Examination of these genetic profiles to see if there are mutations in the gene K-RAS and N-RAS. Both of these genes are very important in cell proliferation.
“If the active cell continues or can not stop can become cancerous,” he said.
In addition to determining the therapeutic targets, molecular diagnostics are also useful for monitoring therapy that has been given.
Genetic testing can be done by taking samples from biopsies or blood samples. From the existing data in the laboratory Kalgen, according to Ahmad, nearly 50 percent of lung cancer patients have mutations in K-RAS gene.